金城医药：子公司获得普罗雌烯乳膏药品补充申请批准通知书

Core Viewpoint - Jincheng Pharmaceutical's subsidiary received approval for changes to the formulation and quality standards of Progestin Cream, which may enhance product competitiveness but will not significantly impact current financial performance [1] Company Summary - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received a notification from the National Medical Products Administration regarding the approval of a supplemental application for Progestin Cream [1] - The approved changes include modifications to the types and amounts of excipients, process changes, and quality standard adjustments [1] Industry Summary - Progestin is a strictly local acting estrogen used for the treatment of menopausal genitourinary syndrome [1] - The approval of the supplemental application is expected to improve the product's competitiveness in the market [1]